Nearly one in five smart pump customers say they would not buy their current pump again, with one exception, according to a new report from healthcare market research firm KLAS. The recent survey ...

Though "smart" infusion pumps are supposed to make intravenous medication and fluid administration safer and streamline the process of documenting infusions in patient records, just one manufacturer ...

This technological achievement takes patient care and safety to a new level. ATLANTA, March 21, 2017 /PRNewswire-USNewswire/ -- Grady is proud to be Metro Atlanta's first hospital to successfully ...

The use of smart pump technology has been proven to reduce the frequency of errors in the administration of intravenous drugs. But software glitches and other potentially dangerous problems persist.

Washington, D.C.--(Newsfile Corp. - December 16, 2024) - The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD will pay a $175 million civil penalty to settle charges ...

The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD has expanded a Class I Alaris recall to cover 15 ...

A new group of recalls for a repair piece installed in some of BD’s Alaris infusion pumps joins more than a dozen others on the long list of serious recalls involving the device in the last decade.

FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...

CareFusion is recalling 7,418 units of its Alaris Syringe infusion pump, a corrective action that the FDA just deemed Class 1. This marks CareFusion's ninth Class 1 recall of an Alaris device since ...